 |
인쇄하기
취소
|
Concerns mounting over delayed review of 576 bioequivalence drugs
Despite the Korea Food and Drug Administration’ pledge that it will complete the reassessment of 576 drugs by 2010, there are growing worries over the KFDA’s slow process.
Sources say that of the 576 items whose bioequivalence has yet to be proven, the KFDA has still failed to re-evaluate 141 items as it would take time for more accurate judgment.
Amid this, the Korea Medical Association...
Sources say that of the 576 items whose bioequivalence has yet to be proven, the KFDA has still failed to re-evaluate 141 items as it would take time for more accurate judgment.
Amid this, the Korea Medical Association...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.